Quarterly Result12 Feb 2026, 10:52 pm
Lupin Ltd Reports Strong Q3 FY2026 Results with 26.4% YoY Sales Growth
AI Summary
Pharma major Lupin Limited reported its financial performance for the quarter ending December 31, 2025. The company's sales stood at INR 71,005 Mn, representing a 26.4% YoY growth. EBITDA was INR 23,766 Mn with a margin of 33.5%, and PAT was INR 15,220 Mn, up 42.1% YoY. Lupin's U.S. sales contributed 44% of the global sales, with 31,132 Mn INR in Q3 FY2026.
Key Highlights
- Sales of INR 71,005 Mn, up 26.4% YoY
- EBITDA of INR 23,766 Mn with a margin of 33.5%
- PAT of INR 15,220 Mn, up 42.1% YoY
- U.S. sales contributing 44% of global sales
- Received 1 ANDA approvals from the U.S. FDA and launched 3 products in the quarter in the U.S.